Table 1.

Pancreatic cancer patient demographics, 1987–2017

	Total (N = 454)	III (n = 174)				IV (n = 280)
		i.a. chemo	UAP	Chi-squared test	p value	i.a. chemo	UAP	Chi-squared test	p value
n	454	95	79	–	–	138	142	–	–
Male	267	43	48	48.44	< 0.01	79	92	104.68	< 0.01
Female	187	52	31	40.60	< 0.01	59	50	42.96	< 0.01
Tumor size > 5 cm	207	2	9	5.87	–	44	152	157.88	< 0.01
Tumor size > 8 cm	89	1	8	6.64	–	17	63	38.37	< 0.01
Adeno ca	391	91	63	136.66	< 0.01	114	123	200.64	< 0.01
Endocrine ca	7	0	0	–	–	3	4	0.29	–
n.a.	56	9	11	2.89	< 0.1	17	19	4.68	< 0.05
No metastases	175	95	79	–	–	0	0	–	–
1 organ metastasized	123	0	0	–	–	83	47	65.53	< 0.01
2 organs metastasized	111	0	0	–	–	46	53	35.18	< 0.01
3 organs metastasized	33	0	0	–	–	8	29	13.78	< 0.01
4+ organs metastasized	15	0	0	–	–	1	13	9.75	< 0.01
Peritoneal carcinosis	79	0	1	–	–	16	52	28.35	< 0.01
Ascites (medium to severe)	36	5	6	1.02	< 0.9	9	16	3.72	< 0.1
Pretreated with systemic chemotherapy	174	8	24	13.89	< 0.01	42	55	34.37	< 0.01
Gemcitabine	51	2	5	2.04	–	17	27	8.41	< 0.01
5-FU (+ leucovorin)	29	3	9	4.52	–	8	9	1.06	< 0.9
FOLFIRINOX	8	1	0	0.83	–	0	7	6.66	–
FOLFOX	2	0	0	–	–	0	2	1.93	–
Erlotinib	8	0	1	1.19	–	0	7	6.66	–
Cisplatin	6	0	0		–	2	4	0.71	–
Others (irinotecan, PEFG, POO, navelbine, ardalan, novantron, GEMOX, Nab-paclitaxel, COSS96, fluroblastin, farnesylproteintransferase, FAM, endoxan, ELF, ACO, Etoposid, paclitaxel, IFNalpha, lok.Hyperthermia)	85	6	13	5.35	< 0.025	32	34	15.57	< 0.01
Regional chemotherapy	454	95	79	–	–	138	142	–	–
Cisplatin/adriamycin/mitomycin	454	95	79	–	–	138	142	–	–
Additional cycles with gemcitabine	60	0	27	–	–	0	33	–	–

Patient groups similarity was testet according to Pearson’s Chi-square test. Patient characteristics with p values < 0.05 were accepted as equably distributed. Characteristics that were found in less than five patients per group could not be tested